IE990286A1 - Diagnosis of irritable bowel syndrome based on demonstrated central cholinergic supersensitivity. - Google Patents
Diagnosis of irritable bowel syndrome based on demonstrated central cholinergic supersensitivity.Info
- Publication number
- IE990286A1 IE990286A1 IE990286A IE990286A IE990286A1 IE 990286 A1 IE990286 A1 IE 990286A1 IE 990286 A IE990286 A IE 990286A IE 990286 A IE990286 A IE 990286A IE 990286 A1 IE990286 A1 IE 990286A1
- Authority
- IE
- Ireland
- Prior art keywords
- cholinergic
- ibs
- subject
- challenge
- diagnosis
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/61—Growth hormones [GH] (Somatotropin)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
An in vitro method for the diagnosis of irritable bowel syndrome (IBS) in a subject suspected of having IBS comprises identifying in said subject a dysfunction of central cholinergic receptors, characterised by the subject's growth hormone response to a cholinergic challenge drug more especially an acetylcholinesterase inhibitor such as pyridostigmine or galanthamine. The response is measured by estimating the level of growth hormone in a sample of blood or a blood fraction obtained from said subject following said challenge. When the subject is a premenopausal female, the diagnosis is carried out during the follicular phase of the menstrual cycle.
Description
Diagnosis of irritable bowel syndrome based on demonstrated central cholinergic supersensitivity
This invention relates to the diagnosis and therapy of irritable bowel syndrome (IBS), in particular to classic colonic irritable bowel syndrome.
IBS is the most common reason for referral to gastroenterology clinics and affects 10-12% of the whole population. To date systematic efforts to determine its aetiology have failed. No consistent biochemical or physiological abnormalities have been io demonstrated and many gastroenterologists describe it as a functional disorder, without an organic basis.
IBS can be described as a condition of the gastrointestinal tract characterised by a disorder of gut motility or rate of movement along the gastrointestinal tract, which may be either delayed or increased. Accordingly, IBS is not characterised by any consistent abnormality in the gut.
The degree of psychological abnormality attributed to patients with IBS varies from study to study. At the inventors’ Clinic using standardised diagnostic criteria (Diagnostic and Statistical ManualIll; American Psychiatric Association, Washington DC) approximately 30% of IBS patients have been found to have psychiatric illness, whilst using less rigorous diagnostic criteria others have found higher rates of illness ( Chaudhury, N.A. and Truelove, S.C., QJMed 1962, 31, 307OPEN TO PUBUC- INSPECTION
UNOEP
SECTION 23 7:.3.7 23
I 7ΪΤ 631¾ ! JNL NOA.
322: Gomez, J. and Dally, P„ BMJ 1977, 1, 1451-1453). The most common diagnoses in the group are depression and anxiety disorders.
It has been shown that patients with predominantly upper IBS type symptoms, usually referred to as non-ulcer dyspepsia, have an abnormality involving central serotonergic receptors (Dinan, T.G., Yatham, L.N., Barry, S., Chua, A. and Keeling, P.W.N., Scand. J. Gastroenterol. 1990,25,541-544; EP-B 0 419 237). The abnormality involves increased sensitivity of these receptors and is associated with a delay in solid phase gastric emptying (Dinan T.G. et al, BMJ 1992, io 305,280-282)
Lower or colonic IBS frequently runs a chronic course and can result in multiple unpleasant and expensive investigations. Treatment is frequently ineffective and usually involves high fibre diets, colofac and antidepressants. Pharmacological treatments directly target is the bowel but are in general rather non-specific, given the fact that the pathophysiology is poorly understood.
Previous studies indicate that the cholinergic release of GH is enhanced in depression and obsessive compulsive disorders (Cooney, J., Lucey, J., O’Keane, V., Dinan, T.G., 1997, Biol. Psychiat. 42, 82720 833).
Diagnosis of IBS cannot currently be made with accuracy in patients who suffer from co-existent depression or obsessive compulsion disorder.
The invention provides an in vitro method for the diagnosis of irritable bowel syndrome (IBS) in a subject suspected of having IBS, which method comprises identifying in said subject a dysfunction of central cholinergic receptors, characterised by the subject’s growth hormone response to a cholinergic challenge drug, said response being measured by estimating the level of growth hormone in a sample of blood or a blood fraction obtained from said subject following said challenge, with the proviso that when the subject is a premenopausal female, the diagnosis is carried out during the follicular phase of the io menstrual cycle.
The method according to the invention demonstrates that central cholinergic responses are significantly enhanced in patients with IBS thereby providing a means of readily diagnosing a subject suffering from IBS.
The results described herein suggest that drugs which act centrally to block cholinergic receptors, without having any direct action on the gut, may be effective in treating IBS.
In the case of premenopausal females the method should be conducted in the follicular phase of the menstrual cycle, as responses alter throughout the cycle in healthy women (O’Keane, V. and Dinan, T.G., 1992, J. Clin. Endocrinol. Metab. 75, 11-14).
Preferably, the cholinergic challenge drug is an acetylcholinesterase inhibitor.
Acetylcholine (ACh) is an important transmitter in the gut and some treatment strategies focus on this peripheral receptor system (Kinnier, W.J., Kachur, J.F., Audia, V.H., Kaiser, C., 1989 Med. Res. Revs. 9, 325-342). It is also an important neurotransmitter in the brain and to date no research has focused on central cholinergic function in IBS. The inventors examined central cholinergic function in patients with a diagnosis of IBS, using a neuroendocrine strategy which they have previously described in detail (O’Keane, V. and Dinan, T.G., 1992 supra).
io The release of growth hormone (GH) from the anterior pituitary gland is regulated by GH releasing hormone (GHRH) and somatostatin (SS)(Hartman, M.L., Veldius, J.D., Thomer, M.O., 1993 Horm, Res. 40, 205-235). The former stimulates and the latter inhibits GH release. ACh inhibits, through muscarinic receptors, the release of
SS and thereby stimulates GH release.
Further, preferably, the cholinergic challenge drug is pyridostigmine.
As described in the following Example pyridostigmine, the acetylcholinesterase inhibitor, was used to enhance cholinergic transmission and thereby stimulate GH release in patients with IBS and appropriate comparison groups.
Other acetylcholinesterase inhibitors such as galanthamine may also be used. Indeed, galanthamine has less side-effects than pyridostigmine.
The pyridostigmine, when such is used, is preferably administered as a single dose in an amount of at least 60 mg, more especially 120 mg, to effect said cholinergic challenge.
The blood fraction is preferably plasma or serum.
The GH is suitably measured by an immunoassay method.
Thus, the GH response is suitably measured by enzyme immunossay or radio immunoassay.
The immunoassay methods in accordance with the invention may be carried out using any known format, such as, for example, beads, dipsticks, membranes, particles, plates, rods, strips, etc.
For example, insolubilised or solid phase antibody as used in accordance with the invention is suitably bound to a bead, dipstick, membrane, plate, particle, rod, tube, well, or the like of plastics material or glass in a manner per se.
More specifically, the insolubilised from of the antibody comprises said antibody adsorbed on a surface adapted for protein adsorption. The surface may be a bead, membrane, particle, plate rod, tube, well or the like and of a material as hereinbefore specified.
Suitably the surface comprises a plastic microtitration plate or strip adapted for protein adsorption wherein the immunochemical reaction and the estimation of the GH or release of the GH on the insolubilised form of the antibody, depending on the method used.
The relevant surface may be coated directly with an optimum dilution of monoclonal antibody or polyclonal antibody.
The estimation of the bound GH derived from the sample can be carried out by enzymatic, fluorometric, luminometric or radiometric assay, using enzymes, fluorochromes, light-emitting probes or radio labels, respectively.
The labelled agents for use in the assays according to the invention are prepared in conventional manner or are purchased from appropriate suppliers. Such labelled agents are normally in the form of conjugates such as enzyme-labelled antibodies for use in competitive binding assays. The labelled agent is also suitably an antibody covalently linked to a radio label for use in a radiometric assay.
The GH response as measured in the method according to the invention is blocked by a muscarinic antagonist.
The invention also provides a test kit or pack for diagnosis of IBS in a subject suspected of having IBS, which comprises an amount of a cholinergic challenge drug for administering to one or more subject(s) being investigated for IBS and sufficient to elicit a growth hormone response characteristic of central cholinergic dysfunction.
Preferably, the cholinergic challenge drug is an cetylcholinesterase inhibitor, more especially pyridostigmine.
Also preferably the test kit or pack includes a muscarinic antagonist.
The accompanying figure shows the growth hormone response to pyridostigmine (120mg) in patients with irritable bowel syndrome ( V), patients with inflammatory bowel disease (Δ) and healthy comparison subjects (□).
The invention will be further illustrated by the following
Example.
Example
Twelve patients with IBS were chosen at random from the Gastroenterology Clinic at St. James’s Hospital, Dublin and fulfilled the io following criteria. They must have had at least 3 months lower abdominal pain and alteration of bowel habit in the absence of endoscopic, ultrasound or X-ray evidence of gastrointestinal structural abnormality. All were negative for occult blood, leucocytes, ova or parasites in stools, endocrine disease, collagen disease, somatic myopathy or any other illness likely to explain symptoms. All were free of present or past psychiatric illness, specifically they were not depressed or suffering from obsessive compulsive disorder. All were medication free for at least 6 weeks prior to testing.
Two groups of comparison subjects were recruited to take part in the study. Group 1 consisted of 12 age-and-sex matched healthy volunteers. Group 2 consisted of 7 patients with inflammatory bowel disease.
The test procedure was as follows. An 18g cannula was inserted in a forearm vein at 0830 hours and the subject relaxed for 30 min. before baseline blood for GH estimation was drawn. At this point pyridostigmine 120mg was administered orally and further blood for GH measurement was taken at+60,+90,+120 and+180min. GH was assayed, blind to subject status, by a double antibody radioimmunoassay (Salvatore, R. In: Laron and Butenandt Eds Evaluation of Growth Hormone Secretion Basel: Karger 1983). Visual analogue scales were used to rate patient symptoms during the test.
io The accompanying figure shows the GH response to pyridostigmine challenge. As can be clearly seen patients with IBS increased GH levels way in excess of that seen in either healthy volunteers or in patients with inflammatory bowel disease. Measuring response as the increase in GH relative to baseline patients with IBS had amean±SEMof 29.l±6.8mU/l whilst healthy volunteers had a mean response of 8.9±2.4mU/l and inflammatory bowel disease patients 7.8 ±2.2mU/l. Eight of the 12 IBS patients experienced an increase in IBS symptoms during the test. No relationship was established between this symptom increase and the GH response. Three of the patients with inflammatory bowel disease developed significant colicky abdominal pain during the test, whilst side-effects in healthy subjects were minimal.
Central cholinergic responses are significantly enhanced in patients with IBS. That the method according to the invention does assess central muscarinic response is evidenced by the fact that such response is blocked by muscarinic antagonists.
Claims (12)
1. CLAIMS: 1. An in vitro method for the diagnosis of irritable bowel syndrome (IBS) in a subject suspected of having IBS, which method comprises identifying in said subject a dysfunction of central cholinergic receptors
2. A method according to Claim 1, wherein the cholinergic challenge drug is an acetylcholinesterase inhibitor.
3. A method according to Claim 1 or 2, wherein the cholinergic challenge drug is pyridostigmine. 15
4. A method according to Claim 3, wherein the pyridostigmine is administered as a single dose in an amount of at least 60mg to effect said cholinergic challenge. 5. Having IBS, which comprises an amount of a cholinergic challenge drug for administering to one or more subject(s) being investigated for IBS and sufficient to elicit a growth hormone response characteristic of central cholinergic dysfunction.
5. A method according to Claim 3 or 4, wherein the amount of pyridostigmine administered as a single dose to effect the cholinergic 20 challenge is 120mg 5 characterised by the subject’s growth hormone response to a cholinergic challenge drug, said response being measured by estimating the level of growth hormone in a sample of blood or a blood fraction obtained from said subject following said challenge, with the proviso that when the subject is a premenopausal female, the diagnosis is carried out during the io follicular phase of the menstrual cycle.
6. The method according to any preceding claim, wherein the growth hormone is measured by an immunoassay method.
7. A method according to any preceding claim, wherein the growth hormone response is blocked by a muscarinic antagonist.
8. A test kit or pack for diagnosis of IBS in a subject suspected of
9. A test kit or pack according to Claim 8, wherein the cholinergic io challenge drug is an acetylcholinesterase inhibitor.
10. A test kit or pack according to Claim 8 or 9, wherein the cholinergic challenge drug is pyridostigmine.
11. A test kit or pack according to any one of Claims 8-10, which includes a muscarinic antagonist. . is
12. A method according to Claim 1 for the diagnosis of IBS in a subject suspected of having IBS, substantially as hereinbefore described and exemplified.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE990286A IE990286A1 (en) | 1999-04-07 | 1999-04-07 | Diagnosis of irritable bowel syndrome based on demonstrated central cholinergic supersensitivity. |
AU36678/00A AU3667800A (en) | 1999-04-07 | 2000-04-06 | Diagnosis of irritable bowel syndrome based on demonstrated central cholinergic supersensitivity |
PCT/IE2000/000038 WO2000060360A2 (en) | 1999-04-07 | 2000-04-06 | Diagnosis of irritable bowel syndrome |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE990286A IE990286A1 (en) | 1999-04-07 | 1999-04-07 | Diagnosis of irritable bowel syndrome based on demonstrated central cholinergic supersensitivity. |
Publications (1)
Publication Number | Publication Date |
---|---|
IE990286A1 true IE990286A1 (en) | 2000-11-01 |
Family
ID=11042038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE990286A IE990286A1 (en) | 1999-04-07 | 1999-04-07 | Diagnosis of irritable bowel syndrome based on demonstrated central cholinergic supersensitivity. |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU3667800A (en) |
IE (1) | IE990286A1 (en) |
WO (1) | WO2000060360A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002062345A1 (en) * | 2001-02-05 | 2002-08-15 | Janssen Pharmaceutica N.V. | Use of galantamine for accelerating transport of intraluminal content |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL115113A (en) * | 1995-08-31 | 2002-11-10 | Israel State | 3-carbamoyloxy pyridinium derivatives and pharmaceutical compositions containing them |
WO1998030243A1 (en) * | 1997-01-08 | 1998-07-16 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
-
1999
- 1999-04-07 IE IE990286A patent/IE990286A1/en not_active IP Right Cessation
-
2000
- 2000-04-06 WO PCT/IE2000/000038 patent/WO2000060360A2/en unknown
- 2000-04-06 AU AU36678/00A patent/AU3667800A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU3667800A (en) | 2000-10-23 |
WO2000060360A3 (en) | 2001-01-04 |
WO2000060360A2 (en) | 2000-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Eggertsen et al. | Screening for thyroid disease in a primary care unit with a thyroid stimulating hormone assay with a low detection limit. | |
MORRIS III et al. | Clinical utility of thyrotropin-receptor antibody assays: comparison of radioreceptor and bioassay methods | |
Hickie et al. | Clinical and subclinical hypothyroidism in patients with chronic and treatment-resistant depression | |
US6268223B1 (en) | Assay for detecting damage to the central nervous system | |
US5484707A (en) | Assay for free secretory component and methods for monitoring organ rejection | |
Cook et al. | Clinical utility of the dexamethasone suppression test assessed by plasma and salivary cortisol determinations | |
US5403848A (en) | Diagnosis and treatment of a disorder of the gastrointestinal tract | |
Desai et al. | Autoimmune thyroid disease in childhood: a study of children and their families | |
WO2004015420B1 (en) | Method for diagnosing multiple sclerosis | |
Wagner et al. | Slow metabolic deterioration towards diabetes in islet cell antibody positive patients with autoimmune polyendocrine disease | |
US20010051345A1 (en) | Method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses | |
Jacobson et al. | Duration of positive urine for ***e metabolite after ophthalmic administration: implications for testing patients with suspected Horner syndrome using ophthalmic ***e | |
JP4122419B2 (en) | Method for detection of Helicobacter pylori and hailmani in stool, saliva samples and biopsy materials | |
IE990286A1 (en) | Diagnosis of irritable bowel syndrome based on demonstrated central cholinergic supersensitivity. | |
Khoo et al. | Differences in the levels of TSH‐binding inhibitor immunoglobulins in goitrous and agoitrous autoimmune thyroiditis after twelve months of l‐thyroxine therapy | |
JP3706913B2 (en) | Diagnostic Kit for Schizophrenia | |
Robeva et al. | Metanephrine and normetanephrine urine excretion in patients with PCOS | |
JP2004069672A (en) | Method and kit for measuring oxide appolipoprotein ai and oxide lipoprotein containing it | |
Carlson et al. | D-Xylose hydrogen breath tests compared to absorption kinetics in human patients with and without malabsorption | |
Rosenbaum et al. | The clinical use of thyroid autoantibodies | |
JP3458512B2 (en) | Method for estimating change in bone density or method for diagnosing osteoporosis and reagent kit used therefor | |
EP2006682B1 (en) | Diagnosis of acute enteritis by determination of intestinal fatty acid-binding protein in the blood | |
Swanson et al. | Increased Intestinal Permeability and Decreased Resiliency of the Intestinal Barrier in Alcoholic Liver Disease | |
EP0720850A1 (en) | Method for the diagnosis of a dysfunction of 5-HT 1A receptors | |
RU2246112C2 (en) | Method for biochemical detecting the degree of chronic hepatitis activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM9A | Patent lapsed through non-payment of renewal fee |